Haruko Obokata was reportedly questioned by police in Japan today. The questioning relates to the STAP cell scandal that led to the retraction of two Nature papers. As first author of the papers, Obokata and other authors had reported that they could make IPSC-like cells simply via acid or other stress treatment. However, it is […]
Obokata questioned by police over STAP cell fiasco Read More »
Clinical research on Type I Diabetes is one of the most exciting and promising areas of stem cells and regenerative medicine for human disease. Two of the coolest companies out there in this arena have been ViaCyte and BetaLogics (owned by J&J). For more on ViaCyte see my interview with President and CEO Paul Laikind
ViaCyte on the Rise: First Diabetes Trial Data & Acquires BetaLogics IP Read More »
The patent dispute on CRISPR between UC/Jennifer Doudna and The Broad/Feng Zhang has been the subject of major attention including in a recent piece on Stanford Center for Law & Biosciences Blog. There is a lot of confusion over this important CRISPR dispute so I turned to a patent expert for their take on this via an interview
Patent expert weighs in on CRISPR dispute between UC & Broad Read More »
CRISPR is the hottest new biotechnology and the top development of 2015 according to Science Magazine. What will the new year of 2016 bring on the CRISPR front? It’s clear there will be more meetings on CRISPR ethics and policy (heck, we are having one right here at UC Davis on May 26), but what
CRISPR predictions for New Year of 2016 Read More »
A new Cell Stem Cell paper by Victoria L. Mascetti and Roger Pedersen on human-mouse chimera modeling is quite interesting and important. I really enjoyed this short paper, but I do have a reservation about one way that it is being interpreted. The authors show that human pluripotent stem cells (hPSC) including induced pluripotent stem cells
Perspectives on Pedersen Lab Human-Mouse Chimera Paper Read More »
Both before and particularly now after the big human gene editing summit in Washington, D.C. at the National Academy of Sciences, I’ve talked with patients about their views on this new technology including at last week’s World Stem Cell Summit. One of the most striking moments of the DC summit was when the mother of
Just freakin do it: patients voice impatience on CRISPR for genetic diseases Read More »
“Take a Selfie”, has become a catch phrase in pop culture. There is a preoccupation with capturing one’s own existence and key moments in pictures. Another trend is a DIY culture including taking initiative with one’s own health. When combined together we are in the midst of a larger trend in medicine where patients will
Take a medical selfie: a taste of your own medicine Read More »
I just got back from a historic summit on human genetic modification in Washington, D.C. New genetic modification technology, termed CRISPR-Cas9, has both made genetic modification a relatively simple matter for scientists and human genetic modification much more likely in the near future. Heritable human genetic modification could prevent some rare genetic diseases so there
Now we have an interesting panel starting on questions of governance on human gene editing. This will focus on institutional and national levels of governance. Pilar N. Ossorio, University of Wisconsin, Madison, and Morgridge Institute for Research, is introducing the panel. Key question: how should emerging technologies being governed? Jonathan Kimmelman, from McGill, was the first
Live Blogging #GeneEditSummit Day 2 Post #1: Governance of human gene editing Read More »
Now we hear from the scientists on the front lines of CRISPR, covered in this post #2 of the Human Gene Editing Meeting. You can read Post #1 here. Jennifer Doudna starts off the big human gene editing science session on the current state of the human gene editing science and CRISPR. She gave an
Live Blogging #GeneEditSummit Day 1 Post #2: State of the Science, #CRISPR Read More »